Stress caused by unfolded and misfolded proteins in the endoplasmic reticulum (so called "ER stress") intersects with metabolic disease at multiple levels
Thyroid cancer management is evolving to reflect novel developments in imaging, cytology, molecular biology and the outcome of trials evaluating low versus high dose radioiodine therapy
MAIN AUDITORIUM
Chairs: K Boelaert (Birmingham) & P Newey (Oxford)
Muscle is recognised as important endocrine organ and target for the treatment of metabolic syndrome. This symposium will explore the breadth of our new understanding of basic metabolism and investigative clinical data that is currently emerging.
QUEEN'S SUITE A
Chairs: G Lavery (Birmingham) & N Morton (Edinburgh)
As humans have migrated towards the poles, a number of changes have occurred to our endocrine systems which have allowed us to adapt to our new environment, particularly daily and seasonal changes in light intensity and duration. In this symposium we will explore those endocrine systems most affected by latitudinal light levels and our adaptations to overcome these changes
MAIN AUDITORIUM
Chairs: D Renshaw (London) & A McNeilly (Edinburgh)
MicroRNAs have emerged in recent years as key regulators in cancer and endocrine disease. They dramatically modify gene expression at the post-transcriptional stage
QUEEN'S SUITE B
Chairs: M Westwood (Manchester) & S Wood (Glasgow)
It’s not what I eat, it’s what my mother ate. Can maternal lifestyle or nutrition programme life-long metabolic and endocrine problems in their offspring.
Emerging knowledge of the molecular mechanisms in medullary carcinoma of the thyroid is improving our understanding of this condition, which is now impacting on therapy
Stress caused by unfolded and misfolded proteins in the endoplasmic reticulum (so called "ER stress") intersects with metabolic disease at multiple levels
Thyroid cancer management is evolving to reflect novel developments in imaging, cytology, molecular biology and the outcome of trials evaluating low versus high dose radioiodine therapy
MAIN AUDITORIUM
Chairs: K Boelaert (Birmingham) & P Newey (Oxford)
Muscle is recognised as important endocrine organ and target for the treatment of metabolic syndrome. This symposium will explore the breadth of our new understanding of basic metabolism and investigative clinical data that is currently emerging.
QUEEN'S SUITE A
Chairs: G Lavery (Birmingham) & N Morton (Edinburgh)
As humans have migrated towards the poles, a number of changes have occurred to our endocrine systems which have allowed us to adapt to our new environment, particularly daily and seasonal changes in light intensity and duration. In this symposium we will explore those endocrine systems most affected by latitudinal light levels and our adaptations to overcome these changes
MAIN AUDITORIUM
Chairs: D Renshaw (London) & A McNeilly (Edinburgh)
MicroRNAs have emerged in recent years as key regulators in cancer and endocrine disease. They dramatically modify gene expression at the post-transcriptional stage
QUEEN'S SUITE B
Chairs: M Westwood (Manchester) & S Wood (Glasgow)
It’s not what I eat, it’s what my mother ate. Can maternal lifestyle or nutrition programme life-long metabolic and endocrine problems in their offspring.
Emerging knowledge of the molecular mechanisms in medullary carcinoma of the thyroid is improving our understanding of this condition, which is now impacting on therapy